Drugs / anti-KRAS G12V mTCR PBL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03190941 | Sep 2017 → Jun 2027 expected | colon carcinoma, gastric cancer, malignant pancreatic neoplasm, rectal cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-KRAS G12V mTCR PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03190941 ↗ |
| Action | Deplete | “mTCR transduced T cells lyse target cells” NCT03190941 ↗ |
| Modality | Cell therapy | “taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person” NCT03190941 ↗ |
| Route | Intravenous | “Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes” NCT03190941 ↗ |
| Target | KRAS | “mTCR that specifically recognizes the G12V-mutated variant of KRAS” NCT03190941 ↗ |